Lobe Sciences Announces Proposed Shares for Debt Transaction

VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates for diseases with significant unmet medical needs, under a disciplined, pharmaceutical development platform, progressing assets from early development to clinical stages, through focused subsidiary companies, today announced that it has entered into agreements to settle C$1,372,761.20 in outstanding management and director fee debt through the issuance of an aggregate of 12,749,643 common shares of the Company (the "Settlement Shares") at a price of $0.11 per Settlement Share (the "Debt Settlement").